<DOC>
	<DOCNO>NCT00691015</DOCNO>
	<brief_summary>RATIONALE : Giving low dos chemotherapy , monoclonal antibody , radiation therapy donor peripheral blood stem cell transplant help stop growth cancer cell . It may also stop patient 's immune system reject donor 's stem cell . The donated stem cell may replace patient 's immune cell help destroy remain cancer cell ( graft-versus-tumor effect ) . Sometimes transplanted cell donor also make immune response body 's normal cell . Giving tacrolimus , sirolimus , antithymocyte globulin transplant may stop happen . PURPOSE : This phase II trial study side effect give sirolimus together tacrolimus antithymocyte globulin see well work prevent graft-versus-host disease patient hematologic cancer undergo donor stem cell transplant .</brief_summary>
	<brief_title>Sirolimus , Tacrolimus , Antithymocyte Globulin Preventing Graft-Versus-Host Disease Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine incidence severity acute graft-versus-host disease ( GVHD ) HLA-matched -mismatched unrelated donor peripheral blood stem cell transplantation ( PBSCT ) patient hematologic malignancy treat immunosuppressive therapy comprise sirolimus , tacrolimus , anti-thymocyte globulin GVHD prophylaxis . - To determine safety regimen patient 6 month PBSCT . Secondary - To determine time engraftment ( i.e. , platelet absolute neutrophil recovery ) patient treat regimen . - To determine length hospital stay patient within 100 day PBSCT . - To determine incidence infection , include CMV EBV reactivation post-transplant lymphoproliferative disorder , patient treat regimen . - To determine incidence thrombotic microangiopathy veno-occlusive disease patient treat regimen . - To determine incidence chronic GVHD patient treat regimen . - To determine overall disease-free survival patient 2 year PBSCT . - To determine Karnofsky performance status patient baseline various time point PBSCT . - To conduct immunocorrelative study prior various time point PBSCT . OUTLINE : - Conditioning regimen : Patients receive 1 6 conditioning regimen day -9 -3 , base diagnosis treat physician 's preference regard regimen intensity . - Regimen I : Patients receive fludarabine phosphate IV busulfan IV . - Regimen II : Patients undergo total body irradiation ( TBI ) twice daily 8 fraction receive etoposide IV . - Regimen III : Patients undergo TBI twice daily 11 fraction receive cyclophosphamide IV . - Regimen IV : Patients undergo TBI receive fludarabine phosphate IV busulfan IV . - Regimen V : Patients receive carmustine IV , etoposide IV , cytarabine IV , melphalan IV . Some patient also receive rituximab IV . - Regimen VI : Patients receive fludarabine phosphate IV melphalan IV . Some patient also undergo TBI . - Allogeneic peripheral blood stem cell transplantation : Patients undergo filgrastim ( G-CSF ) -mobilized allogeneic peripheral blood stem cell transplantation day 0 . - Graft-versus-host disease prophylaxis ( GVHD ) : Patients receive tacrolimus IV continuously 24 hour orally sirolimus orally begin day -3 continue day 30 day 90 , follow taper absence GVHD . Patients also receive anti-thymocyte globulin IV 4-8 hour day -3 -1 . Blood sample obtain baseline periodically study correlative biomarker study . Samples analyze T-cell immunophenotyping , absolute subset number quantification , multi-parameter flow cytometry evaluation immune reconstitution , T-cell differentiation status , NK-cell recovery , allo-reactivity donor T-cells transplantation , regulatory T-cell reconstitution . After completion study therapy , patient follow periodically 2 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis hematological malignancy , include follow : NonHodgkin lymphoma complete remission ( CR ) partial remission ( PR ) Hodgkin lymphoma CR PR Acute myeloid leukemia ( AML ) acute lymphoblastic leukemia ( ALL ) meeting either follow criterion : In CR Not CR meet follow criterion : Bone marrow blast &lt; 20 % within 4 week transplantation Peripheral blood absolute blast count &lt; 500 per microliter day initiate condition therapy Myelodysplastic syndrome , treat untreated Chronic myeloid leukemia chronic phase accelerate phase Multiple myeloma CR PR Chronic lymphocytic leukemia second great CR PR Myelofibrosis myeloproliferative disorder meet follow criterion : Bone marrow blast &lt; 20 % within 4 week transplantation Peripheral blood absolute blast count &lt; 500 per microliter day initiate condition therapy Patients ascites allow No prior bone marrow ex vivo engineer process graft ( i.e. , CD34+ enrichment , Tcell depletion , etc ) Scheduled undergo peripheral blood stem cell transplantation suitable HLAmatched mismatch unrelated donor , determine treat physician High resolution molecular HLA typing require HLA class I II No one antigen allele mismatch No document uncontrolled CNS disease PATIENT CHARACTERISTICS : ECOG performance status ( PS ) 02 Karnofsky PS 60100 % Creatinine clearance &gt; 50 mL/min Bilirubin &lt; 3 time upper limit normal ( ULN ) ALT AST &lt; 3 time ULN LVEF &gt; 50 % FVC , FEV_1 , DLCO &gt; 50 % predict Patients home oxygen allow Able cooperate oral medication intake HIV negative No active hepatitis B hepatitis C No known contraindication sirolimus , tacrolimus , antithymocyte globulin PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
	<keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>myelodysplastic/myeloproliferative neoplasm , unclassifiable</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>primary myelofibrosis</keyword>
	<keyword>atypical chronic myeloid leukemia , BCR-ABL negative</keyword>
	<keyword>chronic eosinophilic leukemia</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>chronic neutrophilic leukemia</keyword>
</DOC>